Hepatocellular Carcinoma Drugs are prescribed for cancer patients to minimize side-effects of chemotherapy and kill cancer cells
Hepatocellular carcinoma is one of the most prevalent types of cancer in the world and is one of the most common cancers worldwide. Furthermore, the increased intake of paracetamol and aflatoxin has led to the emergence of novel treatments. The newly developed hepatocellular carcinoma drugs aim to meet the unmet medical needs of people with hepatocellular carcinoma. However, the new drugs have been accompanied by several side effects, including anemia, pneumonia, and low white blood cell counts. Although there are some risks associated with the treatment of HCC, noticeable improvements in patients' health should offset these concerns in the future.
According to the
"Coherent Market Insights"
Global Industry Insights, Trends, Outlook, and Opportunity Analysis of Hepatocellular
Carcinoma Drugs Market.
Hepatocellular Carcinoma Drugs Market
The main molecular targets of hepatocellular
carcinoma drugs include transforming growth factor-b (TGF-b), TGF-b receptors,
and epidermal growth factor receptors. The hepatitis B virus is also a risk
factor for developing HCC. It has been found that the cancer drugs used to
treat the disease can also reduce the level of hepatitis C.
Several treatments are currently available to
patients with hepatocellular carcinoma. The new therapies include sorafenib
tosylate and bortezomib, which are both PD1 inhibitors. For instance, in
January 2022, Merck & Co., Inc., a major pharmaceutical firm in the U.S.,
disclosed the conclusion of its Phase III clinical trial on KEYTRUDA, an
anti-PD-1 therapy, revealing that cancer patients should be monitored
frequently after the administration of hepatocellular carcinoma drugs as a
single agent. However, there are several side effects of these drugs, including
diarrhea, anemia, and pneumonia. These side effects are considered mild to
moderate, but could hamper the treatment of patients with hepatocellular
carcinomas.
Hepatocellular carcinoma drugs are expected to
provide relief from side effects such as diarrhea, low white blood cell count,
and constipation. The adverse effects of these medicines, however, may make the
demand for these medications less attractive in the future. Hepatocellular
cancer drugs are the most popular form of treatment for hepatocellular
carcinoma.
Comments
Post a Comment